409082-11-7

Basic information

• Product Name: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE
• Synonyms: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE;Benzeneacetonitrile, 2-Methyl-5-nitro-
• CAS NO: 409082-11-7
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.172
• Mol File: 409082-11-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 361.613 °C at 760 mmHg
• Flash Point: 172.498 °C
• Appearance: /
• Density: 1.226 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE(409082-11-7)
• EPA Substance Registry System: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE(409082-11-7)

Safety Data

• Hazardous Substances Data: 409082-11-7(Hazardous Substances Data)

Usage

General Description

2-(2-Methyl-5-nitrophenyl)acetonitrile is a chemical compound with the molecular formula C10H8N2O2. It is a yellow solid that is widely used in organic synthesis and pharmaceutical research. 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE is commonly used as an intermediate in the production of various pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as a building block in the synthesis of various complex organic molecules. The compound has potential biological and pharmacological activities, and its derivatives are studied for their potential applications in medicine and drug development. Additionally, it is important to handle this compound with care, as it can be harmful if ingested or inhaled, and can cause skin and eye irritation upon contact.

Upstream product

• 77324-87-9 methyl 2-methyl-5-nitrobenzoate 
• 1975-52-6 5-nitro-o-toluic acid 
• 22474-47-1 (2-methyl-5-nitro-7-phenyl)methanol 
• 58966-24-8 2-(chloromethyl)-4-nitrotoluene 
• 773837-37-9 sodium cyanide 
• 409082-10-6 (2-methyl-5-nitrophenyl)-methyl methylsulfonate 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 

Downstream Products

• 287119-83-9 2-(2-Methyl-5-nitrophenyl)acetic acid 
• 1021535-31-8 3-(5-amino-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 850451-77-3 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one 
• 1021532-47-7 N-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenylcarbamothioyl)benzamide 
• 1185281-07-5 3-(5-isothiocyanato-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185281-04-2 C₁₈H₁₆N₄O 
• 1185855-70-2 (E)-1-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenyl)-2-hydroxyguanidine 
• 1185281-06-4 N-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenyl)-1H-imidazole-1-carboxamide 
• 1185279-54-2 3-(5-(5-isopropyl-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185280-98-1 3-(5-(3-isopropyl-1,2,4-oxadiazol-5-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185281-08-6 N-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenylcarbamothioyl)isobutyramide 
• 1185280-85-6 3-(5-(5-cyclopropylisoxazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185279-51-9 3-(5-(5-cyclopropyl-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185280-06-1 3-(5-{[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]amino}-2-methylphenyl)-1,7-dimethyl-1,2-dihydro-1,6-naphthyridin-2-one 

Relevant articles and documents

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS

The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF beta , SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2 beta kinases.